Microcap Ledger Alzamend Neuro, Inc. $ALZN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Atlanta, GA
- Fiscal year end
- April 30
- Shares outstanding
- 4,825,723 [10-Q 2026-09-10]
What the company doesAI summary of filing
Alzamend Neuro is a clinical-stage biopharmaceutical company developing two drug candidates for Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. AL001, its lead product, is an ionic cocrystal of lithium licensed from the University of South Florida and is currently in Phase II clinical trials; ALZN002, a cell-based immunotherapy vaccine also licensed from the same institution, is in early-stage clinical development. The company is pre-revenue and does not expect to generate material revenue for several years, if at all, and would require successful clinical trial results and FDA regulatory approval before commercializing either product. [10-K 2026-07-22]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 3 months to Jul 2026 | — | −$3.03M | −$1.14M | $7.59M | [10-Q 2026-09-10] |
| FY ended Apr 2026 | — | −$8.77M | −$8.07M | $710.7K | [10-K 2026-07-22] |
| FY ended Apr 2025 | — | −$4.51M | −$6.57M | $3.95M | [10-K 2026-07-22] |
- Quarterly cash burn
- −$1.14M
- Cash runway Estimate
- ~20 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-12-10 | 5,432,797 | [10-Q 2024-12-11] |
| 2025-03-07 | 6,597,507 | [10-Q 2025-03-10] |
| 2025-07-22 | 2,896,432 | [10-K 2025-07-22] |
| 2025-09-10 | 3,139,861 | [10-Q 2025-09-10] |
| 2025-12-09 | 3,801,604 | [10-Q 2025-12-09] |
| 2026-03-11 | 3,804,741 | [10-Q 2026-03-11] |
| 2026-07-22 | 4,791,525 | [10-K 2026-07-22] |
| 2026-09-10 | 4,825,723 | [10-Q 2026-09-10] |
- Shelf registration
- S-1 filed 2026-08-21; no effectiveness notice found in EDGAR [S-1 2026-08-21]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-08-03. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-08-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-08-03] |
| 2026-03-20 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-20] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-26 | Ault Milton C Iii | sell | 2,000 | $1.56 | [4 2026-08-31] |
| 2026-04-14 | Ault Milton C Iii | buy | 108,388 | $1.00 | [4 2026-04-16] |
| 2025-12-23 | Ault Milton C Iii | sell | 1,851 | $2.07 | [4 2025-12-30] |
| 2025-12-19 | Horne William B. | sell | 3,333 | $2.12 | [4 2025-12-23] |
| 2025-10-23 | Mcgrath Lynne Fahey | sell | 30 | $2.29 | [4 2025-10-24] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 8-K | Regulation FD disclosure |
| 2026-09-10 | 10-Q | Quarterly report |
| 2026-08-28 | PRE 14A | Proxy statement |
| 2026-08-21 | S-1 | Registration statement |
| 2026-08-03 | 8-K | Material agreement entered; Listing notice or transfer; Unregistered sale of equity |
| 2026-07-22 | 10-K | Annual report |
| 2026-07-21 | 8-K | Other events |
| 2026-04-17 | 8-K | Shareholder vote results |
| 2026-03-20 | 8-K | Listing notice or transfer |
| 2026-03-11 | 10-Q | Quarterly report |
| 2026-03-06 | 424B5 | Prospectus or prospectus supplement |
| 2026-03-06 | 8-K | Material agreement entered |
Alerts for $ALZN
Email me when Alzamend Neuro, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.